{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 35,
   "id": "49daab27-6a0a-446a-a53b-0aea6ca94965",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The autoreload extension is already loaded. To reload it, use:\n",
      "  %reload_ext autoreload\n"
     ]
    }
   ],
   "source": [
    "# %load_ext autoreload\n",
    "# %autoreload 2"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "547fc87e-ac05-48d9-8494-d8fc331c17ad",
   "metadata": {},
   "outputs": [],
   "source": [
    "import sys\n",
    "import os\n",
    "from googleapiclient.discovery import build\n",
    "from typing import List, Literal, Optional\n",
    "from pydantic import BaseModel, Field\n",
    "from IPython.display import JSON\n",
    "\n",
    "import nest_asyncio\n",
    "nest_asyncio.apply()\n",
    "\n",
    "sys.path.append(os.path.abspath(\"..\"))\n",
    "from src import YouTubeHelper, llm_client, text_to_speech, io_manager, schemas"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "82a3fc4a-b8ac-4a2c-80f2-785e5d269d52",
   "metadata": {},
   "outputs": [],
   "source": [
    "# import importlib\n",
    "# importlib.reload(src.io_manager)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "d5e526cf-5bb4-4c8a-8b04-1ca8dfae0a74",
   "metadata": {},
   "outputs": [],
   "source": [
    "class StockMetric(BaseModel):\n",
    "    label: str\n",
    "    value: str\n",
    "\n",
    "class StockEntry(BaseModel):\n",
    "    ticker: str\n",
    "    company_name: str\n",
    "    sentiment: Literal[\"Bullish\", \"Bearish\", \"Neutral\"]\n",
    "    thesis: str\n",
    "    sources: List[str]\n",
    "    metrics: List[StockMetric]\n",
    "    voiceover_script: Optional[str] = None\n",
    "    # voiceover_script: Optional[str] = Field(default=None, exclude=True)\n",
    "\n",
    "class MarketReport(BaseModel):\n",
    "    report_title: str\n",
    "    stocks: List[StockEntry]\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "198c0744-8883-4937-be27-9212b6c47eea",
   "metadata": {},
   "outputs": [],
   "source": [
    "with open(\"../reports/2026-02-06_transcripts.txt\", 'r', encoding='utf-8') as file:\n",
    "    transcript = file.read()\n",
    "\n",
    "with open(\"../prompts/combined_transcript_summary.md\", 'r', encoding='utf-8') as file:\n",
    "    system_prompt = file.read()\n",
    "\n",
    "with open(\"../prompts/generate_transcript_for_ticker.md\", 'r', encoding='utf-8') as file:\n",
    "    ticker_prompt_template = file.read()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "0b8899e1-c3ee-4401-9c65-e58e86435a0e",
   "metadata": {},
   "outputs": [],
   "source": [
    "# MarketReport.model_json_schema()\n",
    "# system_prompt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "8f6f71ab-6da7-46fa-bc12-e63d4005123a",
   "metadata": {},
   "outputs": [],
   "source": [
    "# ai_schema = MarketReport.model_json_schema()\n",
    "# ai_schema['$defs']['StockEntry']['properties'].pop('voiceover_script', None)\n",
    "# ai_schema\n",
    "\n",
    "llm = llm_client.LLMClient(provider=\"google\")\n",
    "json_report = llm.chat(system_prompt=system_prompt, user_message=transcript, response_schema=MarketReport) \n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "7a4145d6-6880-4611-b669-addf547fdde2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/json": {
       "report_title": "State of the Market: Disruptive GLP-1 Compounding and Pharmaceutical Legal Battles",
       "stocks": [
        {
         "company_name": "Hims & Hers Health, Inc.",
         "metrics": [
          {
           "label": "Monthly Price (Initial)",
           "value": "$49 or $59"
          },
          {
           "label": "Monthly Price (Ongoing)",
           "value": "$99"
          },
          {
           "label": "Cash on Balance Sheet",
           "value": "$1 billion"
          },
          {
           "label": "Technology Platform",
           "value": "Liposomal technology via Strive"
          },
          {
           "label": "Regulatory Framework",
           "value": "503A and 503b compounding facilities"
          }
         ],
         "sentiment": "Bullish",
         "sources": [
          "Asymmetric Investing by Travis Hoium"
         ],
         "thesis": "Hims & Hers is aggressively disrupting the weight loss market by launching a compounded oral semaglutide product that bypasses branded SNAC technology patents using liposomal technology from Strive. Despite legal threats from Big Pharma, the company's $1 billion cash reserve and a board filled with former FDA and Big Pharma executives suggest a high-conviction move to leverage 503A and 503b compounding laws.",
         "ticker": "HIMS",
         "voiceover_script": null
        },
        {
         "company_name": "Novo Nordisk",
         "metrics": [
          {
           "label": "Key Patent Technology",
           "value": "SNAC technology (oral delivery)"
          },
          {
           "label": "Business Exposure",
           "value": "Tens of billions of dollars in weight loss market"
          }
         ],
         "sentiment": "Bearish",
         "sources": [
          "Asymmetric Investing by Travis Hoium"
         ],
         "thesis": "Novo Nordisk faces significant legal and competitive risks as compounding pharmacies scale production of semaglutide alternatives. Legal action against competitors like HIMS carries the asymmetric risk that patents could be invalidated or compounding practices could be legally validated in court, threatening the company's multibillion-dollar weight loss franchise.",
         "ticker": "NVO",
         "voiceover_script": null
        },
        {
         "company_name": "Eli Lilly and Company",
         "metrics": [
          {
           "label": "Legal Precedent",
           "value": "Lawsuits against compounders denied with prejudice"
          }
         ],
         "sentiment": "Neutral",
         "sources": [
          "Asymmetric Investing by Travis Hoium"
         ],
         "thesis": "Eli Lilly is cited as a precedent in the pharmaceutical industry's battle against compounders, with several of their lawsuits against compounding pharmacies having been denied with prejudice, indicating a difficult legal road for Big Pharma to stop these competitors.",
         "ticker": "LLY",
         "voiceover_script": null
        }
       ]
      },
      "text/plain": [
       "<IPython.core.display.JSON object>"
      ]
     },
     "metadata": {
      "application/json": {
       "expanded": false,
       "root": "root"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "display(JSON(json_report.model_dump()))\n",
    "# json_report"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "d3084b1c-e1b9-4533-a74d-ce73c5d26fd5",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Generating scripts for 3 stocks...\n",
      "-> Processing HIMS...\n",
      "-> Processing NVO...\n",
      "-> Processing LLY...\n"
     ]
    }
   ],
   "source": [
    "def generate_all_scripts(report: MarketReport):\n",
    "    print(f\"Generating scripts for {len(report.stocks)} stocks...\")\n",
    "    \n",
    "    for stock in report.stocks:\n",
    "        script_prompt = io_manager.load_formated_stock_prompt(stock)\n",
    "        # print(script_prompt)\n",
    "        llm = llm_client.LLMClient(provider=\"google\")\n",
    "\n",
    "        script_text = llm.chat(\n",
    "            system_prompt=\"You are a financial scriptwriter.\",\n",
    "            user_message=script_prompt\n",
    "        )\n",
    "        \n",
    "        # 3. Store it back in the object\n",
    "        stock.voiceover_script = script_text.strip()\n",
    "        # text_to_speech.text_to_voice()\n",
    "\n",
    "    return report\n",
    "\n",
    "# generate_all_scripts(json_report)\n",
    "json_report_full = generate_all_scripts(json_report)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "id": "fcabd53a-d418-4430-90e0-9dfc46c45c4b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/json": {
       "report_title": "State of the Market: Disruptive GLP-1 Compounding and Pharmaceutical Legal Battles",
       "stocks": [
        {
         "company_name": "Hims & Hers Health, Inc.",
         "metrics": [
          {
           "label": "Monthly Price (Initial)",
           "value": "$49 or $59"
          },
          {
           "label": "Monthly Price (Ongoing)",
           "value": "$99"
          },
          {
           "label": "Cash on Balance Sheet",
           "value": "$1 billion"
          },
          {
           "label": "Technology Platform",
           "value": "Liposomal technology via Strive"
          },
          {
           "label": "Regulatory Framework",
           "value": "503A and 503b compounding facilities"
          }
         ],
         "sentiment": "Bullish",
         "sources": [
          "Asymmetric Investing by Travis Hoium"
         ],
         "thesis": "Hims & Hers is aggressively disrupting the weight loss market by launching a compounded oral semaglutide product that bypasses branded SNAC technology patents using liposomal technology from Strive. Despite legal threats from Big Pharma, the company's $1 billion cash reserve and a board filled with former FDA and Big Pharma executives suggest a high-conviction move to leverage 503A and 503b compounding laws.",
         "ticker": "HIMS",
         "voiceover_script": "HIMS presents a compelling bullish thesis. Utilizing liposomal technology to navigate patent hurdles, they are scaling compounded oral semaglutide. Backed by one billion dollars in cash, this strategic move leverages compounding laws. HIMS is a high-growth disruptor."
        },
        {
         "company_name": "Novo Nordisk",
         "metrics": [
          {
           "label": "Key Patent Technology",
           "value": "SNAC technology (oral delivery)"
          },
          {
           "label": "Business Exposure",
           "value": "Tens of billions of dollars in weight loss market"
          }
         ],
         "sentiment": "Bearish",
         "sources": [
          "Asymmetric Investing by Travis Hoium"
         ],
         "thesis": "Novo Nordisk faces significant legal and competitive risks as compounding pharmacies scale production of semaglutide alternatives. Legal action against competitors like HIMS carries the asymmetric risk that patents could be invalidated or compounding practices could be legally validated in court, threatening the company's multibillion-dollar weight loss franchise.",
         "ticker": "NVO",
         "voiceover_script": "NVO faces a bearish outlook as legal battles with compounding pharmacies intensify. Suing competitors like Hims carries asymmetric risk, potentially invalidating critical SNAC technology patents. This exposure threatens their multibillion dollar weight loss franchise, creating a significant strategic headwind."
        },
        {
         "company_name": "Eli Lilly and Company",
         "metrics": [
          {
           "label": "Legal Precedent",
           "value": "Lawsuits against compounders denied with prejudice"
          }
         ],
         "sentiment": "Neutral",
         "sources": [
          "Asymmetric Investing by Travis Hoium"
         ],
         "thesis": "Eli Lilly is cited as a precedent in the pharmaceutical industry's battle against compounders, with several of their lawsuits against compounding pharmacies having been denied with prejudice, indicating a difficult legal road for Big Pharma to stop these competitors.",
         "ticker": "LLY",
         "voiceover_script": "LLY maintains a neutral outlook as the firm faces strategic headwinds regarding competition. Eli Lilly serves as a precedent for pharmaceutical battles against compounders, with several lawsuits recently denied with prejudice. This underscores a difficult legal road ahead."
        }
       ]
      },
      "text/plain": [
       "<IPython.core.display.JSON object>"
      ]
     },
     "metadata": {
      "application/json": {
       "expanded": false,
       "root": "root"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "display(JSON(json_report_full.model_dump()))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "id": "f006803c-c4e4-4fae-9601-b2537a78dc7a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "\"1. [INTRO]\\nThe weight loss market is undergoing a massive shift as GLP-1 compounding pharmacies challenge pharmaceutical giants. New legal battles are redefining how semaglutide is distributed, creating massive volatility for key players in the space. We are analyzing the disruptive power of compounding laws and the potential patent risks facing industry leaders. Stay tuned as we break down the high-conviction moves and legal precedents shaping the future of this multibillion-dollar healthcare sector.\\n\\n2. [HIMS]\\nHIMS is a disruptive force with a strong Bullish sentiment as it scales compounded oral semaglutide. By utilizing liposomal technology, they successfully navigate patent hurdles while offering a compelling ninety-nine dollar ongoing monthly price point. The company is weaponized with a one billion dollar cash reserve and a board stacked with former FDA officials. This strategic leverage of 503A and 503b compounding laws positions Hims and Hers as a high-growth leader in weight loss.\\n\\n3. [NVO]\\nNVO currently carries a Bearish outlook as legal tensions with compounding pharmacies reach a boiling point. The company is aggressively suing competitors, but this carries an asymmetric risk of invalidating their critical SNAC technology patents. If court rulings favor the compounders, Novo Nordiskâ€™s multibillion-dollar weight loss franchise faces immediate exposure. This strategic headwind threatens their market dominance as production of semaglutide alternatives continues to scale rapidly across the entire healthcare landscape.\\n\\n4. [LLY]\\nLLY remains at a Neutral sentiment as the pharmaceutical giant navigates a complex regulatory environment. Eli Lilly serves as a sobering legal precedent, with several of their lawsuits against compounding pharmacies being denied with prejudice. This indicates a difficult legal road for Big Pharma to stop smaller, high-speed competitors. Despite their massive market share, these judicial setbacks suggest that stopping the rise of compounded alternatives will be an uphill battle for Lilly.\\n\\n5. [OUTRO]\\nThe collision between Big Pharma and compounding disruptors is just beginning to reshape the healthcare market. Whether it is the aggressive growth of HIMS or the legal vulnerabilities of NVO and LLY, the stakes are incredibly high. Investors must closely monitor these patent battles and regulatory shifts to stay ahead of the volatility. Don't forget to like and subscribe for more deep dives into the disruptive technologies driving today's most competitive stock markets.\""
      ]
     },
     "execution_count": 29,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# combine subtranscripts\n",
    "# generate voiceover\n",
    "prompt = \"\"\"\n",
    "Role: Financial Video Scriptwriter\n",
    "Task: Write a segmented YouTube script. Each segment must be roughly 30 seconds (70-75 words).\n",
    "\n",
    "REPORT: {report_title}\n",
    "DATA: {full_json_dump}\n",
    "\n",
    "CONSTRAINTS FOR EVERY SEGMENT:\n",
    "- Word Count: 70-75 words.\n",
    "- Structure: 4-5 punchy sentences.\n",
    "- Tone: Professional and fast-paced.\n",
    "- Content: Mention the Ticker, Sentiment, and at least one key Metric.\n",
    "\n",
    "OUTPUT FORMAT:\n",
    "Return a list of segments.\n",
    "1. [INTRO]: Hook the viewer on the overall theme.\n",
    "2. [STOCK TICKER]: Focus on the thesis and data.\n",
    "... (repeat for each stock)\n",
    "3. [OUTRO]: Summary and call to action.\n",
    "\"\"\"\n",
    "\n",
    "final_prompt = prompt.format(\n",
    "    report_title=json_report_full.report_title,\n",
    "    full_json_dump=json_report_full.model_dump_json(indent=2)\n",
    ")\n",
    "\n",
    "ft = llm.chat(\n",
    "            system_prompt=\"You are a financial scriptwriter.\",\n",
    "            user_message=final_prompt\n",
    "        )\n",
    "ft"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "id": "05cd6e9c-5410-4cc5-a602-b2d086a9702c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'State of the Market: Disruptive GLP-1 Compounding and Pharmaceutical Legal Battles'"
      ]
     },
     "execution_count": 28,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "json_report_full.report_title"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "dc9dbe4b-323d-4088-b1f7-b93e65c860ee",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "da8415b6-c045-47f1-b1d2-3e94c7111080",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "53b5cbe0-53a9-4f78-ab91-12585749c4bc",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "61ce2e7f-3dc9-413a-905c-9f1f32fc7588",
   "metadata": {},
   "outputs": [],
   "source": [
    "from src import utils\n",
    "def save_json(report, filename):\n",
    "    json_data = report.model_dump_json(indent=2)\n",
    "    \n",
    "    # 3. Write the file\n",
    "    with open(utils.PROJECT_ROOT/ \"reports\" / filename, \"w\", encoding=\"utf-8\") as f:\n",
    "        f.write(json_data)\n",
    "save_json(json_report_full, \"test.json\")\n",
    "# io_manager.save_json(json_report_full, \"test.json\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "c1b73733-0bee-4994-bfb4-8e77ebb4a9ca",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "b1f6365b-a65e-4d53-b983-c7059517739d",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.12"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
